Literature DB >> 20434409

Development and validation of a rapid and sensitive assay for simultaneous quantification of midazolam, 1'-hydroxymidazolam, and 4-hydroxymidazolam by liquid chromatography coupled to tandem mass-spectrometry.

Miroslav Dostalek1, Joyce S Macwan, Shripad D Chitnis, Ileana A Ionita, Fatemeh Akhlaghi.   

Abstract

Midazolam is an ultra short acting benzodiazepine derivative and a specific probe for phenotyping cytochrome P450 (P450) 3A4/5 activity. A rapid, sensitive, and selective LC-MS/MS method was developed for simultaneous quantitation of midazolam and its metabolites (1'-hydroxymidazolam and 4-hydroxymidazolam). Deuterated (D5) analog of midazolam was utilized as an internal standard. Sample preparation either from human plasma (100 microL) or liver microsomal incubations involved a simple protein precipitation using acetonitrile (900 microL) with an average recovery of >90% for all compounds. The chromatographic separation was achieved using Zorbax-SB Phenyl, Rapid Resolution HT (2.1 mm x 100 mm, 3.5 microm) and a gradient elution with 10 mM ammonium acetate in 10% methanol (A) and acetonitrile (B). The flow rate was 0.25 mL/min and total run time was 5.5 min. Calibration curves were linear over the concentration range of 0.100-250 ng/mL. The lower limit of quantitation (LLOQ) was 0.1 ng/mL for all three analytes. The accuracy and precision, estimated at LLOQ and three concentration levels of quality control samples in six replicates, were within 85-115%. In conclusion, a robust, simple and highly sensitive analytical method was developed and validated for the analysis of midazolam and its metabolites. This method is suitable for characterizing the P450 3A4/5 activity in vitro or in human pharmacokinetic studies allowing administration of smaller doses of midazolam. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20434409     DOI: 10.1016/j.jchromb.2010.04.001

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.

Authors:  Rohitash Jamwal; Suzanne M de la Monte; Ken Ogasawara; Sravani Adusumalli; Benjamin B Barlock; Fatemeh Akhlaghi
Journal:  Mol Pharm       Date:  2018-06-11       Impact factor: 4.939

2.  Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus.

Authors:  Miroslav Dostalek; Michael H Court; Bingfang Yan; Fatemeh Akhlaghi
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

3.  Development and validation of a sensitive assay for analysis of midazolam, free and conjugated 1-hydroxymidazolam and 4-hydroxymidazolam in pediatric plasma: Application to Pediatric Pharmacokinetic Study.

Authors:  Ganesh S Moorthy; Harini Jogiraju; Christina Vedar; Athena F Zuppa
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-09-28       Impact factor: 3.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.